Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
09:00am, Wednesday, 18'th Feb 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
03:41am, Friday, 06'th Feb 2026
MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights ex
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
01:31pm, Thursday, 29'th Jan 2026
/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
MoneyShow's Best Investment Ideas For 2026: Part 5
12:30pm, Thursday, 15'th Jan 2026
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Tuesday, 13'th Jan 2026
MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stuart Tross Sells 47,006 Shares of MannKind (NASDAQ:MNKD) Stock
04:56am, Sunday, 11'th Jan 2026
MannKind Corporation (NASDAQ: MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average price o
MannKind Provides Business Updates and 2026 Growth Drivers
08:05am, Thursday, 08'th Jan 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD
04:34am, Monday, 05'th Jan 2026
Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ: MNKD) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
06:16pm, Wednesday, 24'th Dec 2025
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (MNKD +0.00%), executed an exercise and immediate sale of 65,804 common shares for a transaction value of approximat
MannKind Shares FUROSCIX® Business Updates
08:05am, Tuesday, 23'rd Dec 2025
FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock
05:03am, Sunday, 21'st Dec 2025
MannKind Corporation (NASDAQ: MNKD - Get Free Report) CEO Michael Castagna sold 65,804 shares of the firm's stock in a transaction dated Wednesday, December 17th. The shares were sold at an average pr
Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)
03:30am, Monday, 08'th Dec 2025
Virax Biolabs Group (NASDAQ: VRAX - Get Free Report) and MannKind (NASDAQ: MNKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two bus
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients
11:46am, Wednesday, 03'rd Dec 2025
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX R
